Author:
Kim Jeong Eun,Hong Yong Sang,Lee Jae-Lyun,Kim Kyu-Pyo,Park Seong Joon,Sym Sun Jin,Shin Dong Bok,Lee Jeeyun,Park Young Suk,Ahn Jin Seok,Kim Tae Won
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Keating GM, Duggan ST, Curran MP (2012) Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy. CNS Drugs 26(9):787–790
2. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19(10):1609–1617
3. NCCN (2011) NCCN Clinical practice guidelines in oncology: antiemesis. Version 1.2011
4. Decker GM, DeMeyer ES, Kisko DL (2006) Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 4(1):35–41, 52
5. Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473–2482
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献